pharmaceutical investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
pharmaceutical investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
VIDEO - BTV Visits Atlas Salt, Graphene Manufacturing, Telescope Innovations, Nevada Organic Phosphate, Maple Gold, Intrepid Metals and Nine Mile Metals
